This is an old revision of this page, as edited by MB(talk | contribs) at 00:01, 2 August 2020(clean up, rmv redlink portal). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 00:01, 2 August 2020 by MB(talk | contribs)(clean up, rmv redlink portal)
Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2 agonists.[1]
The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat).[1] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.[1] Indacaterol/mometasone was approved for medical use in the European Union in May 2020,[1] and in Japan in June 2020.[2]